刘举,男,博士、研究员(医药学)、硕士研究生导师。教育部学位中心学位论文评审专家,辽宁省医药原料药制备工程技术研究中心副主任,辽宁省小分子靶向药物研发工程研究中心常务副主任,沈阳市科技计划项目评审专家,沈阳市高层次人才(拔尖人才)。2003年毕业于鞍山师范学院,获应用化学学士学位。2006年毕业于辽宁大学,获有机化学硕士学位。2018年毕业于沈阳药科大学,获药物化学博士学位。2006年至今于辽宁大学澳门老牌娱乐官网入口下载从事药物化学相关的科研和教学工作。主持辽宁省科技厅项目1项、辽宁省教育厅项目1项、沈阳市科技局项目1项、辽宁大学青年科学基金项目1项。作为主要成员先后参与国家、辽宁省及沈阳市等各类科技项目20余项。指导学生完成多项国家级、省级和校级 “大学生创新创业训练计划” 项目。在国内外期刊发表论文70余篇,其中以第一作者或通讯作者发表SCI论文30余篇。申请国家发明专利30余项,其中以第一发明人提交国家专利申请13项,授权9项。获辽宁省自然科学学术成果奖一等奖和三等奖各1项。获沈阳市自然科学学术成果奖三等奖1项。
研究方向:基于靶点的新型抗肿瘤和抗菌药物的设计与开发;天然产物结构修饰及全合成;药物制备工艺优化; 抗肿瘤药物的体内外筛选及作用机制等药理学研究。
承担课题:
1. 辽宁省教育厅项目, 含哒嗪酮结构的选择性c-Met激酶抑制剂的设计,合成与生物活性研究, LJC201907, 2019.10 –2022.09, 结题, 主持。
2. 辽宁省科技厅项目, 新型选择性c-Met激酶抑制剂的设计合成和抗肿瘤活性研究,2019-ZD-0191, 2019.10 –2022.09, 结题, 主持。
3. 沈阳市科技局项目, 基于4-苯氧基吡啶为核心骨架的选择性c-Met激酶抑制剂的设计合成和抗肿瘤活性研究, 18-013-0-03, 2018.1-2019.12, 结题, 主持。
4. 辽宁大学校青年基金, 芳基取代的吡喃衍生物的合成及抗肿瘤活性研究, LDQN201436, 结题, 主持。
5. 国家自然科学基金项目, 青年项目, 基于晶体结构设计的, 具有吡啶并[2,3-d]嘧啶结构的新型EGFR激酶抑制剂的合成及构效关系研究, 21807055, 2019.01-2021.12, 结题, 参加。
6. 国家十二五“重大新药创制”科技重大专项, 一类抗耐药菌新药马来酸环嘧耐平临床前研究,2011ZX09102-007-02, 结题, 参加。
7. 国家十一五“重大新药创制”科技重大专项, 一类抗肿瘤新药藤甲酰苷候选药物研究, 2009ZX09103-030,2009.1-2011.12, 结题, 参加。
8. 辽宁省自然科学基金,新型c-KIT蛋白抑制剂吡环替尼(PN17-1)对胃肠道间质瘤作用机制研究,2022JH2/101300090,2022.08-2025.07, 在研, 参加。
9. 辽宁省自然科学基金,新型EGFR激酶抑制剂类抗非小细胞肺癌药物的设计、合成及药理活性研究,2022-MS-169,2022.08-2025.07, 在研, 参加。
10. 辽宁省教育厅青年基金项目, 新型LpxC抑制剂类抗菌剂的设计、合成和生物活性研究, LQN201709, 2017.09-2020.08, 结题, 参加。
11. 辽宁省科技厅项目,辽宁省医药原料药制备工程技术研究中心科技平台建设, 2017051022,2018.01-2020.12, 结题, 参加。
12. 沈阳市重大科技成果转化项目,作用于肿瘤新靶点Bcr-AblT315I和c-Kit T670I 突变体蛋白激 酶抑制剂普环替尼临川前项目转化, 20-203-5-44, 2020.07-2022.06,结题, 参加。
13. 沈阳市科技局项目, 具有对Bcr-Abl和c-Kit蛋白酪氨酸激酶双重抑制作用的一类抗肿瘤新药环苯替尼的研究, F16-182-9-00, 2016.01-2018.12, 结题, 参加。
发表论文:
1. Ju Liu, Yadong Zhang, Yan Zhu, Lu Tian, Mingrui Tang, Jiwei Shen, Shi Ding, Ye Chen. Research Progress on Small Molecules Targeting TRK Kinase Inhibitors. Current Medicinal Chemistry, 2023, 30(10): 1175–1192.
2. Shi Ding, Ziye Gao, Ziqiang Hu, Rui Qi, Xiangshan Zheng, Xiaoyong Dong, Mingjuan Zhang, Jiwei Shen, Tian Long, Yan Zhu, Lu Tian, Wenshan Song, Ruoqing Liu, Ying Li, Jiahuan Sun,Wenwen Duan, Ju Liu (corresponding author), Ye Chen. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors. European Journal of Medicinal Chemistry, 2022, 238, 114492.
3. Ju Liu, Fang Liu, Zhen Li, Chunyan Li, Shuang Wu, Jiwei Shen, Huan Wang, Siyuan Du, Hao Wei, Yunlei Hou, Shi Ding, Ye Chen. Novel 4-phenoxypyridine derivatives bearing imidazole-4-carboxamide and 1,2,4-triazole-3-carboxamide moieties: design, synthesis and biological evaluation as potent antitumor agents. Bioorganic Chemistry, 2022, 120, 105629.
4. Shi Ding, Xiaoyong Dong, Ziye Gao, Xiangshan Zheng, Jingchao Ji, Mingjuan Zhang, Fang Liu, Shuang Wu, Wenshan Song, Ruoqing Liu, Jiwei Shen, Ju Liu (corresponding author), Ye Chen. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl) acrylamide derivatives as selective EGFRL858R/T790M kinase inhibitors. Bioorganic Chemistry, 2022, 118, 105471.
5. Hao Wei, Zhen Li, Fang Liu, Yang Wang, Shi Ding, Ye Chen, Ju Liu (corresponding author). The Role of FTO in Tumors and It’s Research Progress. Current Medicinal Chemistry, 2022, 29(5): 924-933.
6. Liu Ju, Wu Shuang, Wang Huan, Du SiYuan, Li Zhen, Shen JiWei, CHEN Ye, DING Shi. Novel 2,4-diarylaminopyrimidine derivatives containing pyridine moiety: Design, Synthesis, Crystal Structure and Biological Evaluation. Chinese Journal of Structural Chemistry, 2022, 22(2): 132-140.
7. Zhen Li, Fang Liu, Shuang Wu, Shi Ding, Ye Chen, Ju Liu (corresponding author). Research Progress on the Drug Resistance of ALK Kinase Inhibitors, Current Medicinal Chemistry, 2022, 29(14): 2456 - 2475.
8. Xinghua Zhao, Shi Ding, Shengnan Li, Yang Wang, Mingjun Jiang, Ju Liu (corresponding author), Ye Chen. Construction of gambogic acid HPMA Copolymer Coupling drug system and study on anti-tumor activity. Current drug delivery, 2022, 19, 491-507.
9. Yutong Liang, Jiaojiao Zhang, Xinghua Zhao, Ming Wang, Shi Ding, Yang Wang, Ye Chen, Ju Liu (corresponding author). Study on the Slow-release Mometasone Furoate Injection of PLGA for the Treatment of Knee Arthritis. Current drug delivery, 2021, 18(3): 357-368.
10. Xinghua Zhao, Jiaojiao Zhang, Yutong Liang, Jie Li, Shi Ding, Yang Wang, Ye Chen, Ju Liu (corresponding author). Advances in Drug Therapy for Systemic Lupus Erythematosus. Current Medicinal Chemistry, 2021, 28(6), 1251 – 1268.
11. Ju Liu, Yilin Gong, Jiantao Shi, Xuechen Hao, Yang Wang, Yunpeng Zhou, Yunlei Hou, Yajing Liu, Shi Ding, Ye Chen. Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors. European Journal of Medicinal Chemistr, 2020, 194: 112244.
12. Zhen Wang, Jiantao Shi, Xianglong Zhu, Wenwen Zhao, Yilin Gong, Xuechen Hao, Yunlei Hou, Yajing Liu, Shi Ding, Ju Liu (corresponding author), Ye Chen, Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2- carboxamide derivatives as potential c-Met kinase inhibitors. Bioorganic Chemistry, 2020, 105, 104371.
13. Jun Li, Jie Li, Jiaojiao Zhang, Jiantao Shi, Shi Ding, Yajing Liu, Ye Chen, Ju Liu (corresponding author). Design, synthesis and biological evaluation of novel 4-phenoxypyridine derivatives containing semicarbazones moiety as potential c-Met kinase inhibitors, Anti-Cancer Agents in Medicinal Chemistry, 2020, 20(5): 559-570.
14. Ju Liu, Yutong Liu, Xuechen Hao, Yang Wang, Jingchao Ji, Yajing Liu, Shi Ding, Ye Chen,. Design, synthesis and biological evaluation of novel 4-phenoxypyridine derivatives as potential antitumor agents. Archiv der Pharmazie Chemistry in Life Science, 2019, 352 (5): e201800338.
15. Shi Ding, Jingchao Ji, Mingjuan Zhang, Yusheng Yang, Rui Wang, Xinglong Zhu, Lihong Wang, Yi Zhong, Le Gao, Man Lu, Ju Liu (corresponding author), Ye Chen. Exploration of the structure-activity relationship and druggability of novel oxazolidinone-based compounds as Gram-negative antibacterial agents. Archiv der Pharmazie Chemistry in Life Science, 2019, 352(11): e1900129.
16. Ju Liu, Jian-tao Shi, Xuechen Hao, Yutong Liu, Shi Ding, Yang Wang, Ye Chen, Synthesis, crystal structure and antitumour activity of ethyl 2-((2-amino-3-cyano-4-phenethyl-4H- naphtho[1,2-b]pyran-8-yl)oxy)acetate, Journal of Chemical Research, 2018, 42(9): 486-489.
17. Ju Liu, Di Yang, Xiuxiu Yang, Minhua Nie, Guodong Wu, Zhunchao Wang, Wei Li, Yajing Liu, Ping Gong. Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry, 2017, 25: 4475–4486
18. Ju Liu, Minhua Nie, Yanjing Wang, Jinxing Hu, Feng Zhang, Yanlin Gao, Yajing Liu, Ping Gong. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors. European Journal of Medicinal Chemistr, 2016, 123: 431-446.
19. Ju Liu, Xinwei Zhang, Duanzheng Song, Zhiqiang Cai and Yunpeng Zhou. Synthesis of several new 1-arylpyrazolo[3,4-d]pyrimidines containing amide moiety. Journal of Chemical Research, 2016, 40: 92-94.
20. Ju Liu, Xinwei Zhang, Yang Wang, Ye Chen, Meirong Zhang, Zhiqiang Cai, Yunpeng Zhou, Lifeng Xu. A new efficient synthesis of 4-alkoxy-1,6-diaryl-1H-pyrazolo[3,4-d]pyrimidine derivatives. Synthetic Communications, 2015, 45(8): 1009-1017.
第一发明人专利:
1. 一种4,6-二芳基吡喃衍生物及其在制备肝癌药物中的应用, 201611075498.3(授权)
2. 含1,2,4-三嗪酮结构的鬼臼毒素类化合物及其应用, 201710854259.6(授权)
3. 一种4-芳基吡喃衍生物及其制备和应用, 201710119123.0(授权)
4. 含缩氨基脲结构的4-苯氧基吡啶类化合物及其应用, 201810312564.7 (授权)
5. 含吲唑的查尔酮类化合物及其应用, 201810467034 (授权)
6. 含吲哚结构的噻吩并[3,2-d]嘧啶类衍生物及其应用, 201910303838 .0(授权)
7. 含吡啶结构的2,4-二芳氨基嘧啶类衍生物及其应用, 201910601774.2 (授权)
8. 含芳基腙结构的吡唑并[1,5-a]嘧啶类衍生物及其应用, 201910845980.8 (授权)
9. 一种新型取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用, 202010446046.1 (授权)
10. 含哒嗪酮的4-苯氧基吡啶类化合物及其应用, 201811118996.0
11. 一种新型4-苯氨基苯并呋喃并[2,3-d]嘧啶类衍生物及其应用, 201811221240.9.
12. 含3-哒嗪酮、4-哒嗪酮和1,2,4-三嗪酮结构的4-苯氧基吡啶类衍生物及其应用. 201911124253.9.
13. 含喹喔啉酮的4-苯氧基吡啶类化合物及其应用. 202010310205.5.
联系方式:
地址:辽宁省沈阳市崇山中路66号
电话:024-62202469
手机: 13840579525
传真:024-62202469
电邮:liuju1216@126.com